Danazol versus [d-Trp6]GnRH agonist for the management of infertility due to atypical endometriosis

Summary The aim of this study is to assess the impact of atypical endometriosis on fertility as well as the effect of treatment in endometriosis-related infertility. A prospective randomized study comparing the effects of triptorelin (Arvekap, Ipsen) and danazol (Danatrol, Winthrop) was completed recently. The 103 patients (aged 30.9±4.92, range 21–41) who finished the study were divided into three comparable (infertility duration, age) groups. Group A (n=37) received danazol (600 mg/day) for 6 months, Group B (n=32) received triptorelin (3.75 mg) injections, one every 28 days for 6 months, and Group C (n=34) did not receive any kind of treatment. More pregnancies were observed in Group B (65.62%) compared with Group C (20.58%, p=0.00012) but not compared with Group A (54.05%, p=0.05857). The overall monthly fecundity rate in Group B was 0.11, and differences concerning spontaneous abortion rates were not observed. Our results indicate that danazol and triptorelin are equally effective in the treatment of atypical endometriosis-related infertility.